Ionis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Ionis Pharmaceuticals

29/07/2026 17:42

Ionis Pharmaceuticals Inc IONS.OQ reported a quarterly adjusted loss of 69 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 70 cents.  The mean expectation of twenty one analysts for the quarter was for a loss of $1.07 per share. Wall Street expected results to range from $-1.23 to -84 cents per share.
Revenue fell 40.7% to $268.00 million from a year ago; analysts expected $190.67 million. 
Ionis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 69 cents​.
The company reported a quarterly loss of $115 million.
Ionis Pharmaceuticals Inc shares had fallen by 30.3% this quarter and lost 30.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.​ 
In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $89.50, about 38.2% above its last closing price of $55.30
This summary was machine generated from LSEG data July 29 at 04:42 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.07
-0.69
Beat
Mar. 31 2026 
-0.91
-0.56
Beat
Dec. 31 2025 
-1.32
-1.41
Missed
Sep. 30 2025 
-1.23
-0.80
Beat